HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tamoxifen: Will Less Equal More in Women with Precancerous Breast Disease?

Abstract
Similar risk reduction but fewer side effects would predict more uptake and compliance with low (5 mg) versus full (20 mg) dose tamoxifen. Benefit with low dose is demonstrated for perimenopausal/postmenopausal women with intraepithelial neoplasia and high lesion Ki-67. Longer follow-up needed to determine benefit with low lesion Ki-67.See related article by DeCensi et al., p. 3576.
AuthorsCarol J Fabian
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 27 Issue 13 Pg. 3510-3511 (07 01 2021) ISSN: 1557-3265 [Electronic] United States
PMID33926916 (Publication Type: Journal Article, Comment)
Copyright©2021 American Association for Cancer Research.
Chemical References
  • Tamoxifen
Topics
  • Breast
  • Breast Diseases
  • Carcinoma in Situ
  • Female
  • Humans
  • Precancerous Conditions (drug therapy)
  • Tamoxifen (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: